



Joint Seminar: Stem Cell Society and Exploit Technologies



22 March 2012, Thursday
4pm to 5pm (followed by networking social)
Multi-Function Rooms, 2 & 2A, (accessible from corridor linking the sky bridges)
@ Matrix Building, Level 5

Hosted by Dr Steve Oh, Principal Scientist, Bioprocessing Technology Institute

World's First off-the-shelf allogeneic cord-blood stem cell drug CARTISTEM® - Journey to the market.

Dr. Antonio S J Lee
Associate Director – Business Development and R&D Strategy
MEDIPOST Co., Ltd. Seoul, KOREA

Human umbilical cord blood-derived Mesenchymal Stem Cells (hUCB-MSCs) are a robust source for not only giving rise to a new cell type in need but also for secreting various trophic factors which will signal the activation of host's own stem cells for producing required cell types and drive the regenerative process. MEDIPOST has made R&D efforts for over 10 years for developing adult stem cell drugs to meet unmet medical needs in areas such as osteoarthritis, stroke, Alzheimer's disease, bronchopulmonary dysplasia (BPD) and improving the efficacy of hematopoietic stem cell transplantation (HSCT). Through rigorous pre-clinical studies and clinical trials, we have proven the safety and efficacy of hUCB-MSCs as adult stem cell drug materials. The drug products under development include CARTISTEM® for cartilage regeneration, which has completed Phase III clinical trial in Korea and in January 2012, obtained a Biologics License Application (BLA) approval from the Korea FDA. With this historical market-approval, CARTISTEM® has become the world's first allogeneic adult stem cell drug for treating patients with osteoarthritis (OA). CARTISTEM® has also received an Investigational New Drug (IND) clearance from the US-FDA in

February 2011 and the Phase I/IIa clinical trial will soon commence in the U.S. Other hUCB-MSC products named PNEUMOSTEM® for treating Bronchopulmonary Dysplasia (BPD) and NEUROSTEM-AD® for treating Alzheimer's Disease (AD) have both completed Phase I clinical trials in Korea.

Dr. Antonio (Tony) Lee

Associate Director, Business Development and R&D Strategy, is involved in product development, clinical trials, licensing and marketing of human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) technology and products at MEDIPOST. Prior to joining MEDIPOST, Tony held research scientist position at the University of New South Wales, Sydney, Australia working on the pre-clinical adult stem cell transplantation project funded by the Australian National Health and Medical Research Council (NH&MRC). Tony received his PhD in Developmental Biology from the University of Otago, New Zealand.

About Exploit Technologies Pte Ltd (ETPL): Exploit Technologies Pte Ltd (ETPL) is the technology transfer office of the Agency for Science, Technology and Research (A*STAR). Its mission is to support A*STAR in transforming the economy through commercializing R&D. Exploit Technologies enhances the research output of A*STAR scientists by translating their inventions into marketable products or processes. Through licensing deals and spin-offs with industry partners, Exploit Technologies is a key driver of technology transfer in Singapore. It actively engages industry leaders and players to commercialise A*STAR's technologies and capabilities, bridging the gap from Mind to Market. Exploit Technologies' charter is to identify, protect and exploit promising intellectual property (IP) created by A*STAR's research institutes. For more information, please visit <http://www.exploit-tech.com>.